Altimmune Inc
Altimmune Inc (ALT) Covered Calls
Altimmune Inc trades in the Biotechnology industry with an IV Rank of 68.85%, average versus the past year. ALT's highest covered call setup is the $5.00 strike expiring Mar 19, 2027, sorted by theoretical annualized return. It's 275.94% out of the money with 119 days to expiration, a 279.70% return until expiration, and a 857.90% theoretical annualized return. Across the setups shown, annualized returns run from 206.95% to 857.90% at strikes between $2.00 and $10.00, with 56 to 427 days to expiration, as of Nov 20, 2026.
Read more
Running ALT covered calls helps you generate income from Altimmune Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ALT covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If ALT stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ALT covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ALT covered call is worth writing.
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc.
| 2027-03-19 | 119 | 5.00 | 275.94 | 0.05 | 0.30 | 372.00 | 279.70 | 857.90 | -3.76 | +0.29 | 957 | 0.25 |
| 2028-01-21 | 427 | 10.00 | 651.88 | 0.10 | 0.30 | 877.00 | 659.40 | 563.65 | -7.52 | +0.29 | 11,499 | 0.20 |
| 2027-03-19 | 119 | 3.50 | 163.16 | 0.05 | 0.15 | 222.00 | 166.92 | 511.97 | -3.76 | +0.22 | 1,588 | 0.10 |
| 2027-03-19 | 119 | 3.00 | 125.56 | 0.05 | 0.15 | 172.00 | 129.32 | 396.66 | -3.76 | +0.24 | 427 | 0.10 |
| 2028-01-21 | 427 | 7.00 | 426.32 | 0.05 | 0.45 | 572.00 | 430.08 | 367.63 | -3.76 | +0.36 | 2,329 | 0.40 |
| 2027-01-15 | 56 | 2.00 | 50.38 | 0.05 | 0.15 | 72.00 | 54.14 | 352.85 | -3.76 | +0.30 | 14,813 | 0.10 |
| 2027-03-19 | 119 | 2.50 | 87.97 | 0.10 | 0.20 | 127.00 | 95.49 | 292.89 | -7.52 | +0.33 | 398 | 0.10 |
| 2028-01-21 | 427 | 5.50 | 313.53 | 0.05 | 0.45 | 422.00 | 317.29 | 271.22 | -3.76 | +0.37 | 379 | 0.40 |
| 2028-01-21 | 427 | 5.00 | 275.94 | 0.05 | 1.20 | 372.00 | 279.70 | 239.09 | -3.76 | +0.65 | 1,522 | 1.15 |
| 2028-01-21 | 427 | 4.50 | 238.35 | 0.05 | 0.60 | 322.00 | 242.11 | 206.95 | -3.76 | +0.44 | 871 | 0.55 |
As of Nov 20, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank68.85% Moderate
- Market cap (M$)259
- 52 weeks high-79.35%
- 52 weeks low-3.62%
- Analyst recommendationStrong Buy
1.30 - Target price$16.33
1127.82% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-12
- P/E—
- Future P/E—
- EPS (ttm)-0.73
- EPS growth next 5 years12.01%
As of Nov 20, 2026